# US 2025/0084036 A1 · Compound, aldehyde dehydrogenase 2 activator, pharmaceutical composition, and therapeutic and/or prophylactic drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084036 A1
- Document ID: US20250084036A1
- Status: Published application
- Kind: A1
- Application number: 18/728,707
- Filed: 2023-04-21
- Published: 2025-03-13
- Earliest claimed: 2022-04-22
- Assignees: Alchemedicine, Inc.
- Applicants: Alchemedicine, Inc.
- Inventors: Keigo TANAKA
- Web page: https://patentgrep.com/patent/US20250084036A1

## CPC

- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C07D 213/56: Amides
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/10: for osteoporosis
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/40: Acylated substituent nitrogen atom
- C07D 213/64: attached in position 2 or 6
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A compound, a pharmaceutically acceptable salt of the compound, or a prodrug of the compound or the salt, the compound represented by the following formula (1): wherein A is a heterocycle, R1 and R2 are each independently hydrogen, an alkyl, an alkenyl, or an alkynyl, R3 is an alkyl, an alkenyl, or an alkynyl, L is absent or an alkylene, X1 is a halogen, and X2 is hydrogen or a halogen.

## Claims

### Claim 1

A compound, a pharmaceutically acceptable salt of the compound, or a prodrug of the compound or the salt, the compound represented by the following formula (1):
wherein
A is a heterocycle,
R1 and R2 are each independently hydrogen, an alkyl, an alkenyl, or an alkynyl,
R3 is an alkyl, an alkenyl, or an alkynyl,
L is absent or an alkylene,
X1 is a halogen, and
X2 is hydrogen or a halogen.

### Claim 2 (depends on 1)

The compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1, wherein A contains one or more nitrogen atoms as a ring member atom or ring member atoms.

### Claim 3 (depends on 1)

The compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1, wherein A is a five- or six-membered ring.

### Claim 4 (depends on 1)

The compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1, wherein A is an aromatic heterocycle.

### Claim 5 (depends on 1)

The compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1, wherein the compound represented by the formula (1) is a compound represented by the following formula (2):
wherein R1, R2, R3, L, X1, and X2 are as described above.

### Claim 6 (depends on 1)

The compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1, wherein R1 is hydrogen.

### Claim 7 (depends on 1)

The compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1, wherein R2 is hydrogen or an alkyl.

### Claim 8 (depends on 1)

The compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1, wherein R3 is an alkyl.

### Claim 9 (depends on 1)

The compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1, wherein X1 is fluorine.

### Claim 10 (depends on 1)

The compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1, wherein X2 is hydrogen or fluorine.

### Claim 11 (depends on 1)

The compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1, wherein the compound represented by the formula (1) is selected from the group consisting of the following compounds:

### Claim 12 (depends on 1)

The prodrug according to claim 1 or a pharmaceutically acceptable salt of the prodrug, wherein R1 is —CH2—O—PO3H2.

### Claim 13 (depends on 1)

The prodrug according to claim 1 or a pharmaceutically acceptable salt of the prodrug, wherein A contains one or more nitrogen atoms as a ring member atom or ring member atoms, and at least one of the nitrogen atoms is substituted with —CH2—O—PO3H2.

### Claim 14 (depends on 1)

A method for activating aldehyde dehydrogenase 2, the method comprising administering an effective amount of the compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1 to a patient in need thereof.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising the compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1.

### Claim 16 (depends on 1)

A method for treating and/or preventing a disease selected from the group consisting of Fanconi's anemia, osteoporosis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic liver disease, pancreatitis, ischemia-reperfusion injury, peripheral arterial disease, Alzheimer's disease, Parkinson's disease, esophageal cancer, head and neck cancer, pain, and diabetic retinopathy, the method comprising administering an effective amount of the compound, pharmaceutically acceptable salt of the compound, or prodrug of the compound or the salt according to claim 1 to a patient in need thereof.
